Nymox Pharmaceutical

NYMXF · OTC

$0.06+$0.00 (+0.00%)TodayMarket closed · Oct 23, 12:36 PM ET

Prev close $0.06

Latest news

Press releaseJun 17, 10:45 AM ETACCESS Newswire
Nymox's Nymozarfex(TM) Newly Available for Prostate Treatments for Medical Tourists in Collaboration with the Global Alliance of Regenerative Medicine on Roatan Island in the Caribbean
Press releaseJun 2, 4:00 PM ETACCESS Newswire
NYMOX Provides Current Update
Press releaseMar 27, 4:00 PM ETACCESS Newswire
NYMOX Provides Recent Updates
Press releaseMar 11, 1:51 PM ETGlobe Newswire
Nymox Announces Dismissal of Delaware Action Against Ascella
Press releaseDec 17, 9:15 AM ETGlobe Newswire
NYMOX Announces Trading Resumed and New Listing on OTCQB Market
Press releaseAug 30, 9:30 AM ETGlobe Newswire
Nymox Announces Filing of Annual Report
Press releaseJul 18, 1:24 PM ETGlobe Newswire
Nymox Annual Report
Press releaseJul 16, 9:30 AM ETGlobe Newswire
Nymox Required to Resubmit Application to DKMA

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Nymox's Nymozarfex(TM) Newly Available for Prostate Treatments for Medical Tourists in Collaboration with the Global Alliance of Regenerative Medicine on Roatan Island in the Caribbean

NYMOX Provides Current Update

NYMOX Provides Recent Updates

Nymox Announces Dismissal of Delaware Action Against Ascella

NYMOX Announces Trading Resumed and New Listing on OTCQB Market

Nymox Announces Filing of Annual Report

Nymox Annual Report

Nymox Required to Resubmit Application to DKMA